T lymphocytes as potential therapeutic drug carrier for cancer treatment

International Journal of Pharmaceutics

Volumn 311, Issue 1-2, 2006, Pages 229-236

  Steinfeld, Ute ^a   Pauli, Christine ^a   Kaltz, Nikolas ^a   Bergemann, Christian ^b   Lee, Hyeck Hee ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Chemicell GmbH   (Germany)

Author keywords

Doxorubicin; Nanoparticles; T lymphocytes

Indexed keywords

ANTIBIOTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; LACTATE DEHYDROGENASE;

ARTICLE; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CELL DAMAGE; CELL SURVIVAL; CELL TRANSPORT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTROPORATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; LEUKEMIA CELL LINE; NANOPARTICLE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; ELECTROPORATION; FERRIC COMPOUNDS; FLUORESCENT DYES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; MAGNETICS; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS; T-LYMPHOCYTES; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 33644633767     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.12.040     Document Type: Article

References (31)

1. C. Alexiou, A. Schmidt, R. Klein, P. Hulin, C. Bergemann, and W. Arnold Magnetic drug targeting: biodistribution and dependency on magnetic field strength J. Magn. Magn. Mater. 252 2002 363 366
2. R. Asmatulu, M.A. Zalich, R.O. Claus, and J.S. Riffle Synthesis, characterisation and targeting of biodegradable magnetic nanocomposite particles by external magnetic fields J. Magn. Magn. Mater. 292 2005 108 119
3. L. Barraud, P. Merle, E. Soma, L. Lefroncois, S. Guerret, M. Chevallier, C. Dubernet, P. Couvreur, C. Trepo, and L. Vitvitski Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo J. Hep. 42 2005 736 743
4. S. Baron, J. Poast, D. Rizzo, E. Mc Farland, and E. Kieff Electroporation of antibodies, DNA, and other macromolecules into cells: a highly efficient method J. Immunol. Methods 242 2002 115 126
5. C. Bergemann, D. Müller-Schulte, J. Oster, L. Brassard, and A.S. Lübbe Magnetic ion-exchange nano- and microparticles for medical, biomedical and molecular biological applications J. Magn. Magn. Mater. 194 1999 45 52
6. C.C. Berry, S. Charles, S. Wells, M.J. Dalby, and Curtis ASG The influence of transferrin stabilised magnetic nanoparticles on human dermal fibroblasts in culture Int. J. Pharm. 269 2004 211 225
7. K. Birschwein, B. Schlereth, C. Guller, A. Wolf, and R. Lutterbuese MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating establised tumors Mol. Immunol. 43 8 2006 1129 1143
8. J.D.M. Brain, M. Ramon, M. Decamp, Malcom, and E. Warner, Angeline Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species Am. J. Physiol. Lung Cell. Mol. Physiol. 276 1999 L146 L154
9. S.D. Conner, and S.L. Schmid Regulated portals of entry into the cell Nature 422 2003 37 44
10. P.G. Coulie, and T. Connerotte Human tumor-specific T lymphocytes: does function matter more than number? Curr. Opin. Immun. 17 2005 320 325
11. N. Dinauer, S. Balthasar, C. Weber, J. Kreuter, K. Langer, and H. von Briesen Selective targeting of antibody conjungated nanoparticles to leukemic cells and primary T-leukocytes Biomaterials 26 2005 5898 5906
12. Y. Dong, and S.-S. Feng Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anti cancer drugs Biomaterials 26 2005 6068 6076
13. M.E. Dudley, and S.A. Rosenberg Adoptive-cell-transfer therapy for the treatment of patients with cancer Nat. Rev. Cancer 3 2003 666 675
14. M.E. Dudley, J.R. Wunderlich, J.C. Yang, R.M. Sherry, S.L. Topalian, N.P. Restifo, R.E. Royal, U. Kammula, D.E. White, S.A. Mavroukakis, L.J. Rogers, G.J. Gracia, S.A. Jones, D.P. Mangiameli, M.M. Pelletier, Gea-Banaclocje, M.R. Robinson, D.M. Berman, A.C. Filie, A. Abati, and S.A. Rosenberg Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J. Clin. Oncol. 23 2005 2346 2357
15. G.P. Dunn, L.J. Old, and R.D. Schreiber The three Es of cancer immuno-editing Annu. Rev. Immunol. 22 2004 329 360
16. + channel activity FEBS Lett. 569 2004 191 194
17. C.A. Klebanoff, H.T. Khong, P.A. Antony, D.C. Palmer, and N.P. Restifo Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy Trends Immunol. 26 2005 111 117
18. J. Kuball, F.W. Schmitz, R.-H. Voss, E. Antunes Ferreira, R. Engle, P. Guillaume, S. Strand, P. Romero, C. Huber, L.A. Sherman, and M. Theobald Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR Immunity 22 2005 117 129
19. A.S. Lübbe, and C. Bergemann Clinical experiences with magnetic drug targeting: a phase i study with 4′-epidoxorubicin in 14 patients with advanced solid tumors Cancer Res. 56 1996 4686 4693
20. Mitragotri, S., Chambers, E., 2004. International application published under the patent cooperation treaty, International Publication Number WO/032970 A2.
21. S.M. Moghimi, and J. Szebeni Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein binding properties Prog. Lipid Res. 42 2003 463 478
22. N. Rapoport, W.G. Pitt, and J.L. Nelson Drug delivery in polymeric micelles: from in vitro to in vivo J. Control. Release 91 2003 85 95
23. N. Rapoport Combined cancer therapy by micellar-encapsulated drug and ultrasound Int. J. Pharm. 277 2004 155 162
24. J. Rejman, V. Oberle, I. Zuhorn, and D. Hoekstra Size-dependent intrnalization of particles via the pathway of clathrin- and caveolae-mediated endocytosis Biochem. J. 377 2004 159 169
25. S.A. Rosenberg, and M.E. Dudley Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Colloquium Papers 101 2004 14639 14645
26. M.S. Schwartz, and B.K. Matuszewski Determination of a peptide - doxorubicin, prostate-specific antigen activated prodrug, and its active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection: stabilization of the peptide prodrug with EDTA J. Chromatogr. B 780 2002 171 182
27. S.C. Steiniger, J. Kreuter, A.S. Khalansky, I.N. Skidan, A.I. Bobruskin, Z.S. Smirnova, S.E. Severin, R. Uhl, M. Kock, K.D. Geiger, and S.E. Gelperina Chemotherapy of glioblastoma in rats using doxorubicin-loaded nano-particles Int. J. Cancer 109 2004 759 767
28. J. Teissie, N. Eynard, B. Gabriel, and M.P. Rols Electropermeabilization of cell emembranes Adv. Drug Deliv. Rev. 35 1999 3 19
29. I.F. Uchegbu, and A.G. Schätzlein Generics manufacturers should exploit drug delivery technologies for improved therapeutics Bus. Briefing Pharmatech. 2003 203 208
30. H.Y. Wang, and R.-F. Wang Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy Microbes Infect. 7 2005 1056 1062
31. K.Y. Win, and S.S. Feng Effects of particle size and surface coating on cellular uptake of poly-meric nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2004 2713 2722